AHRQ No Evidence to Support Off-Label Uses of Atypical Antipsychotics
"Most off-label use occurs without scientific support."
Drug Safety Issues: Psychotropic Drugs
"Most off-label use occurs without scientific support."
BBC reports that "Up to one in three mental health patients are being over-prescribed drugs, says the Healthcare Commission."
Expert Scientists, Psychiatrists, a Primary Care Physician, a Leading Attorney, will shed light on FDA’s Review of selected data Re: Antidepressants and Adult Suicidality One day prior to FDA’s Advisory Committee Hearing, December 13.
"the first-ever randomized, placebo-controlled trial for the alleviation of post-traumatic stress disorder (PTSD)" reports: "we found that it really offered patients no benefits of any symptoms." [1]
Australian psychiatrist: "Does anyone else see tardive dysmentia after atypicalantipsychotics?"
U.S. Doctors are prescribing the antidepressant, Effexor (150mg) for infants under age one!
The lead story in The New York Times on Thanksgiving day (below) acknowledged several facts demonstrating that children are the victims of major medical malpractice:
"The amount of legal stimulants used as medication and produced in our country has grown 2,000 percent in the last 15 years."
Dr. E. Jane Costello, a professor of psychiatry and behavioral sciences at Duke University, acknowledges: “The system of diagnosis is still 200 to 300 years behind other branches of medicine.” Psychiatry also fails to be guided by an evidence-based positive benefit / risk assessment of its prescribed treatments.
The ethics of this radical drug experiment is being challenged by Dr. Jerald Block, a forthright psychiatrist and experienced system's analyst. His critical appraisal, published in the Bioethics Forum, Hastings Center Report.
AHRP applauds the California chapter of the NAACP for unanimously passing a resolution to end the abusive prescribing of psychotropic drugs for children in foster care!
Today's news report circulated by the media about the negative findings of a much touted, but uncontrolled observational study of depression (STAR*D) promotes the business interests of SSRI antidepressant drug manufacturers.
Antidepressant Makers Withhold Data on Children – Washington Post Thu, 29 Jan 2004 A front page article in The Washington Post addresses the key issue undermining public health and safety. Drug companies conceal unfavorable clinical trial findings: the tests failed to demonstrate that antidepressants are either safe or beneficial for…